International Patent Filing

International patent protection uses several overlapping mechanisms: THE FUNDAMENTAL RULE: patents are territorial — a US patent only covers the US; a Japanese patent only covers Japan; to protect an invention in multiple countries, you must file separate applications in each; there is NO single global patent; PARIS CONVENTION ROUTE (direct national filings): file in your home country; within 12 months, file directly in each foreign country you want protection; claim priority from the home country filing (Paris Convention, Article 4); each country applies its own patentability law; you prosecute separately in each country; PRO: simpler for a small number of countries; CON: expensive and complex for many countries; requires decisions early (within 12 months); PCT ROUTE (Patent Cooperation Treaty): file ONE international application at the national/regional patent office or WIPO; the application is a placeholder for national/regional filings in 150+ PCT contracting states; within 30 months (some countries 31) from priority date, enter national/regional phase in chosen countries; PRO: delays country selection decision by 18 months (12-month priority + 18 months before PCT national phase = 30 months total); international search report (ISR) and written opinion help assess patentability before expensive national filings; CON: additional PCT filing fee; does not eliminate national phase prosecution costs; REGIONAL PATENT SYSTEMS: EPO (European Patent Office): single application covering 38 European states; after grant, validate in chosen countries (per-country validation fee); ARIPO (16 African countries); OAPI (17 African countries); Eurasian Patent Organization (9+ post-Soviet states); GCC (Gulf Cooperation Council); COMBINATION STRATEGY: most applicants file a US provisional, then file a PCT at 12 months, then enter national/regional phase at 30 months in key markets.

The Paris Convention is the foundational treaty enabling international patent priority: HISTORICAL BACKGROUND: Paris Convention for the Protection of Industrial Property (1883); one of the oldest international IP treaties; 179 member states; PRIORITY RIGHT: Article 4: a filing in any member country gives the applicant a 12-month priority right; within 12 months, the applicant may file in any other member country and claim the priority date of the first filing; the foreign application is treated as if filed on the ORIGINAL filing date for prior art purposes; WHAT PRIORITY MEANS: prior art that arose after the priority date cannot be used to reject the foreign application; third-party activities between the priority date and the foreign filing date cannot destroy novelty; IMPORTANT: the 12-month window is strict — missing it means no priority right; some countries have absolute novelty requirements (public disclosure before filing = no patent); even one day late on a Paris Convention filing in a strict novelty country can be fatal; WHAT PRIORITY DOES NOT MEAN: priority does not guarantee the same claims will be granted; each country applies its own patentability law; some countries require additional formalities; some countries (especially pre-AIA equivalents) have different date-of-invention rules; CLAIMING PRIORITY: the foreign application must specifically claim the priority of the earlier application; provide the date, country, and application number; MULTIPLE PRIORITIES: an application may claim priority from multiple earlier applications; each priority must be from within 12 months; DESIGN PATENTS: 6-month priority period (not 12 months) for designs under the Paris Convention; WELL-KNOWN EXAMPLE: US provisional application filed January 1 → PCT filed January 1 of next year claiming US priority → PCT international phase → national phase starting July 1 of year 2 (30 months from priority date).

The PCT system provides a unified filing mechanism and examination process for 150+ countries: PCT OVERVIEW: administered by WIPO (World Intellectual Property Organization); a single PCT application is not a 'world patent' but a placeholder for national/regional filings; allows filing once with extensive national phase entry period; 3,700+ national phase filings per day (PCT applications are ~20% of all patent applications); FILING THE PCT APPLICATION: file at: the USPTO (for US applicants); WIPO (Receiving Office); or a national/regional receiving office in the applicant's country; PCT application content: description; claims; abstract; drawings; ONE SET of requirements for all countries initially; INTERNATIONAL SEARCH REPORT (ISR): the International Searching Authority (ISA — USPTO, EPO, JPO, etc.) conducts a prior art search; results: written opinion (preliminary patentability opinion); ISR identifies relevant prior art; CHAPTER II EXAMINATION (OPTIONAL): applicant may request International Preliminary Examination under Chapter II; more thorough examination; results in an International Preliminary Report on Patentability (IPRP); not required; PCT TIMELINE: MONTH 0: file PCT (at 12 months from priority = PCT has same priority date); MONTHS 12-16: ISR and written opinion received; MONTH 16-22: applicant can amend claims under Article 34 (optional; respond to written opinion); MONTH 22: pay national phase entry fees for chosen countries; MONTHS 30-31: national phase entry deadline (30 months for most countries; 31 for some); NATIONAL PHASE: each country conducts its own examination based on PCT application + ISR + any amendments; national prosecution = separate process per country; COSTS: PCT filing: ~$3,000-$5,000; national phase entry: $2,000-$15,000+ per country (attorney fees + official fees); EPO national phase is particularly expensive ($8,000-$20,000+).

The EPO provides a centralized prosecution route for European patent protection: EUROPEAN PATENT CONVENTION (EPC): the EPO is established under the European Patent Convention; 38 contracting states (EPC states) including all EU members + UK + Switzerland + others; a European patent application is prosecuted centrally at the EPO; on grant, the European patent must be validated in each desired EPC state; FILING AND PROSECUTION: file a European patent application (directly or via PCT national phase); EPO conducts examination (search + examination); single examination in English, French, or German; CLAIMS TRANSLATION: pending harmonization, claims must be translated into all three EPO official languages (English, French, German) upon filing or after grant; description translation required in some states upon validation; GRANT: EPO grants a European patent with a set of approved claims; VALIDATION IN NATIONAL STATES: the patent owner has 3 months after grant to validate in desired EPC states; pay national validation fee + translation requirements for each state; for UK (post-Brexit): UK validates as a separate process (UK-IPO); UNITARY PATENT (effective June 2023): a new option under the EU Patent Regulation; one validation covers 17+ EU member states; replaces individual national validations; NOT available for UK or non-EU EPC states; cost-effective for broad European coverage; lower annual renewal fees than multiple national patents; PROSECUTION STRATEGY: EPO examination is often stricter than USPTO on § 101 equivalent (inventive step); claim scope in Europe may differ from US; EPO oppositions: third parties may challenge a granted European patent within 9 months of grant; RENEWAL FEES: annual renewal fees paid to EPO during prosecution; after grant, national renewal fees to each validation state (or unitary patent renewal).

Building a cost-effective international patent portfolio requires careful strategic analysis: DECISION FRAMEWORK: (a) WHERE ARE YOUR MARKETS: protect where you sell; protect where competitors manufacture; protect where potential licensees operate; (b) WHERE ARE YOUR COMPETITORS: file where competitors are headquartered; file in manufacturing hubs (China, Vietnam, India, Mexico); (c) ENFORCEMENT REALITY: a patent is only as valuable as your ability to enforce it; local litigation costs vary dramatically; China IP enforcement has improved significantly but remains complex; India litigation is slow; US litigation is expensive but powerful; (d) BUDGET CONSTRAINTS: typical cost per country: $3,000-$15,000+ to file + $5,000-$20,000+ to prosecute + $1,000-$5,000/year in renewal fees; total international portfolio: $50K-$500K+ over patent lifetime; PRIORITY MARKETS: US (large market; strong enforcement; expensive to litigate); EPO/Europe (key for tech and pharma; unitary patent reduces validation cost); China (largest manufacturing country; increasing enforcement; critical for most tech companies); Japan (major market for electronics, automotive, pharma); South Korea (electronics, semiconductor hub); COST-SAVING STRATEGIES: use PCT to delay decisions; enter national phase only in highest-priority countries; file continuation applications vs. separate foreign filings when possible; use patent prosecution highway (PPH) to speed prosecution in one country using another country's examination results; PHARMA-SPECIFIC CONSIDERATIONS: file in countries with significant generic manufacturing (India, China, Brazil) to prevent generic competition; file in all countries where the drug will be sold; compulsory license risk assessment for certain markets; PATENT PROSECUTION HIGHWAY (PPH): bilateral agreements between patent offices; if claims allowed in one country, expedited examination in another; reduces prosecution cost and time; available between USPTO and EPO, JPO, KIPO, CNIPA, and others.